Clinical trials: Central Nervous System Tumors
Acromegaly, Pituitary Gigantism
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
To evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of pasireotide LAR in Japanese patients with active acromegaly or pituitary gigantism.
- Trial name
- NCT01673646
- Testing
- Pasireotide LAR
- Where
- 27 sites in Japan
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent or…
- Trial name
- NCT00022360
- Testing
- taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Meningioma
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
Meningioma, the most common intracranial primary tumor of the central nervous system predominantly affects people in their fifties.
- Trial name
- ELUMEN (NCT06126588)
- Testing
- Everolimus
- Where
- 2 sites in France
- Volunteers
- 28 people
- Sponsor
- Central Hospital, Nancy, France
Brain Neoplasm
Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors
This trial studies how well navigated repetitive transcranial magnetic stimulation works in improving motor rehabilitation in participants with brain tumors.
- Trial name
- NCT03606161
- Testing
- Questionnaire Administration, Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Mediastinal Cancer, Metastatic Cancer
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Mediastinal Cancer, Metastatic Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00003941
- Testing
- bleomycin sulfate, filgrastim, cisplatin
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 222 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
NSCLC, Renal Cell Carcinoma
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also…
- Conditions
- NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma
- Trial name
- HYPOGRYPHE (NCT05703269)
- Testing
- single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
- Where
- 34 sites in United States
- Volunteers
- 58 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Melanoma
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
This study will evaluate the efficacy and safety of cobimetinib plus atezolizumab in participants with BRAFV600 wild-type melanoma with central nervous system (CNS) metastases and of cobimetinib plus atezolizumab and vemurafenib…
- Trial name
- NCT03625141
- Testing
- Cobimetinib, Atezolizumab, Vemurafenib
- Where
- 22 sites in Brazil, France and 6 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Brain and Central Nervous System Tumors, Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00002754
- Testing
- monoclonal antibody Me1-14 F(ab')2
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Pituitary Adenoma
AI in Endoscopic Transsphenoidal Surgery
This study focuses on bringing artificial intelligence into the operating room to assist with pituitary tumour surgeries performed through the nose.
- Trial name
- NCT07568366
- Testing
- Live intra-op AI analysis of endoscopic video feed, with output displayed on supplementary monitor
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University College, London
Breast Cancer, Brain Metastases
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain…
- Conditions
- Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT06088056
- Testing
- Combination use of SRT with T-DXd
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Fudan University
Spinal Cord Neoplasms
Alternative Treatment of Giant Spinal Schwannomas
Schwannomas are benign tumors that can reach giant sizes. The diagnosis and treatment of these cases differ from those of small schwannomas.
- Trial name
- NCT02494622
- Where
- Turkey (Türkiye)
- Volunteers
- 18 people
- Sponsor
- Gulsah Karaoren
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
CerebroSpinal Fluid (CSF) Leak
NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery
Postoperative cerebrospinal fluid (CSF) leak is a significant complication of endoscopic endonasal approaches (EEA) to the skull base.
- Trial name
- NoSeal (NCT07216157)
- Testing
- Standard multilayer closure without sealant, Fibrin sealant application, Synthetic polyethylene glycol-based sealant
- Where
- Poland
- Volunteers
- 225 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Advanced Malignant Glioma
A Phase II Study to Treat Advanced Malignant Glioma
The purpose of this study is to evaluate the effectiveness and safety of AMG 102 for the treatment of Advanced Malignant Glioma.
- Trial name
- NCT00427440
- Testing
- AMG 102 at 20 mg/kg, AMG 102 at 10 mg/kg
- Volunteers
- 61 people
- Sponsor
- Amgen
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Infarction, Stroke
Polymorphisms in the Vitamin D System and Health
Polymorphisms in the vitamin D system appear to affect the serum 25(OH)D levels. If so one would expect these polymorphisms to be associated with vitamin D related conditions and diseases, which will be tested in the present…
- Conditions
- Infarction, Stroke, Diabetes, Fracture
- Trial name
- NCT01395303
- Where
- Norway
- Volunteers
- 9,700 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Brain Neoplasms, Non Small Cell Lung Cancer
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
- Trial name
- NCT00234442
- Testing
- Iressa (Gefitinib)
- Where
- 4 sites in Italy
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Brain Tumor, Glioblastoma
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults…
- Conditions
- Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma
- Trial name
- NCT01171469
- Testing
- Dendritic Cells, Imiquimod
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Brain Tumor Recurrent
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma
The goal of this clinical research study is to establish the safety of direct administration of 5-Azacytidine into the fourth ventricle of the brain or resection cavity in patients with recurrent posterior fossa ependymoma.
- Trial name
- 5-AZA (NCT02940483)
- Testing
- 5-Azacytidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Brain Tumor, Cancer
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Protocol # 000860 Background: Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with certain gene mutations (IDH1 or IDH2) are especially aggressive. Better treatments are needed.
- Trial name
- NCT05588141
- Testing
- Zotiraciclib
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.